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Background. Vancomycin-resistant enterococci (VRE) are major therapeutic challenges. Prospective contemporary data characterizing the clinical and molecular epidemiology of VRE bloodstream infections (BSIs) are lacking.
Methods. The Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I) is a prospective observational cohort of
adult patients with enterococcal BSI in 11 US hospitals. We included patients with Enterococcus faecalis or Enterococcus faecium BSI
with ≥1 follow-up blood culture(s) within 7 days and availability of isolate(s) for further characterization. The primary study outcome was in-hospital mortality. Secondary outcomes were mortality at days 4, 7, 10, 12, and 15 after index blood culture. A desirability of outcome ranking was constructed to assess the association of vancomycin resistance with outcomes. All index isolates were
subjected to whole genome sequencing.
Results. Forty-two of 232 (18%) patients died in hospital and 39 (17%) exhibited microbiological failure (lack of clearance in
the first 4 days). Neutropenia (hazard ratio [HR], 3.13), microbiological failure (HR, 2.4), VRE BSI (HR, 2.13), use of urinary catheter (HR, 1.85), and Pitt BSI score ≥2 (HR, 1.83) were significant predictors of in-hospital mortality. Microbiological failure was the
strongest predictor of in-hospital mortality in patients with E faecium bacteremia (HR, 5.03). The impact of vancomycin resistance
on mortality in our cohort changed throughout the course of hospitalization. Enterococcus faecalis sequence type 6 was a predominant multidrug-resistant lineage, whereas a heterogeneous genomic population of E faecium was identified.
Conclusions. Failure of early eradication of VRE from the bloodstream is a major factor associated with poor outcomes.
Keywords. bacteremia; Enterococcus; VRE.
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Vancomycin-resistant enterococci (VRE) are leading causes
of hospital-acquired infections affecting individuals who have
multiple comorbidities or are immunocompromised [1–3]. The
number of infections due to VRE reported in the Americas
and Europe has increased during the last decade, becoming
a significant burden to healthcare systems globally [4–7].
The Centers for Disease Control and Prevention (CDC) estimate that VRE are associated with 54 500 infections and 5400
deaths per year in the United States (US) [8]. Moreover, the
CDC and World Health Organization have included VRE as
high-priority bacteria against which new therapies are urgently
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Contemporary Clinical and Molecular Epidemiology
of Vancomycin-Resistant Enterococcal Bacteremia: A
Prospective Multicenter Cohort Study (VENOUS I)

METHODS
Population

The Vancomycin-Resistant Enterococcal BSI Outcomes Study
(VENOUS I) is a prospective cohort study of adult individuals
(≥18 years old) with ≥1 blood culture positive for Enterococcus
faecalis and Enterococcus faecium from 10 tertiary hospitals in
Houston, Texas and 1 hospital in Detroit, Michigan (September
2016 to March 2018). The hospitals include the largest cancer
center in the US and general hospitals with robust transplant
and cardiovascular programs. Included patients must have ≥1
follow-up blood culture within 7 days after the initial bloodstream episode. Additionally, the initial enterococcal isolate
must be available for further analyses. Only the first episodes
of enterococcal bacteremia were included. Subsequent episodes
of bacteremia were considered a recurrence (defined below) or
new infection if patients were infected with a different species
of Enterococcus.
Data

Clinical information was collected from the electronic medical records at each institution and managed using REDCap
(Research Electronic Data Capture, Vanderbilt University).
Data included demographics, past medical history, comorbid
conditions, history of prior hospitalization (1 year), recent
surgery (a surgical procedure within 2 weeks prior to the
index BSI episode), chemotherapy, and receipt of immunosuppressive medications, including steroids (≥100 mg/day
of hydrocortisone or equivalent given within 2 weeks prior
to index BSI). Severity of illness and comorbidities were assessed using the Pitt BSI and Charlson scores, respectively,
calculated within 48 hours of the index culture [12]. Source
of the enterococcal BSI was based on treating physicians’ final
diagnoses and available clinical/diagnostic data. Empiric
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therapy was defined as antibiotics given prior to final susceptibility results.
Definitive enterococcal antibiotic therapy was defined as antibiotics administered with in vitro activity against enterococci
after final antibiotic susceptibility results or the following combinations: (1) daptomycin plus any of the following: ampicillin,
ampicillin-sulbactam, ertapenem, amoxicillin-clavulanate,
ceftriaxone, or piperacillin-tazobactam and (2) ceftriaxone plus
ampicillin (only E faecalis). The antibiotics should have been
administered for ≥48 hours to be considered for the analysis.
Recurrent BSI was defined as a new positive enterococcal blood
culture in a patient who had a previous negative enterococcal
blood culture during the same hospitalization. Microbiological
failure (MF) was defined as lack of clearance ≥4 days after the
index blood culture [13]. All blood cultures were ordered by the
treating physician and processed in the clinical microbiology
laboratory of each hospital for identification and antibiotic susceptibility testing. All bacterial isolates were sent to the central
study laboratory (Houston, Texas) for confirmatory testing and
genomic characterization.
Outcomes

The main outcome of the study was all-cause in-hospital mortality, defined as death occurring from any cause during admission. This definition was preferred to 30-day mortality in order
to minimize confounding from follow-up as not all centers consistently documented out-of-hospital mortality. Patients were
followed until discharge or in-hospital death. Secondary outcomes were mortality at 4, 7, 10, 12, and 15 days after the index
culture.
Data and Statistical Analyses

Median and interquartile range (IQR) were used as measures of
central tendency and dispersion to describe baseline characteristics. Categorical variables were compared using χ2 or Fisher
exact test when appropriate, and continuous variables were
compared using the Wilcoxon-Mann-Whitney U test. KaplanMeier survival curves were used to estimate the median time
to death and were compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios
(HRs) with 95% confidence interval (CI) for in-hospital mortality and secondary outcomes (independent models were created for each secondary outcome). Patient follow-up started at
the time of blood culture collection and ended when death occurred or the patient was discharged from the hospital, whichever came first. The Cox model was adjusted for comorbidity
indexes (ie, Pitt BSI and Charlson scores). The proportional
hazards assumptions were tested using the Schoenfeld residuals
test. Variable selection was performed using a purposeful selection method using variables depicted in Table 1 and collinearity
was checked during the variable selection process. The residual
variation due to hospital site was accounted by inclusion of the
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needed [9]. Retrospective studies have shown that the presence of vancomycin resistance increases mortality in patients
with enterococcal bloodstream infections (BSIs) compared to
vancomycin-susceptible enterococci (VSE) [3, 10, 11]. However,
the retrospective design of these studies makes it difficult to assess the role of vancomycin resistance in mortality, mostly because data related to patient illness severity and comorbidities
are not widely available, making it difficult to make stringent
adjustments. Additionally, the lack of isolate characterization
and follow-up blood cultures preclude the evaluation of microbiological outcomes and prevent solid interpretations of the
complex dynamics of these infections and response to therapy.
Here, using a prospective cohort of patients with enterococcal
BSI (both VRE and VSE), we sought to provide a comprehensive characterization of the contemporary clinical and genomic
epidemiology of VRE BSIs in a multicenter study conducted in
the US.

Table 1.

Characteristics of Patients With Bloodstream Infections due to Enterococci

Variables

VSE
(n = 176)

VRE
(n = 56)

Total Population
(N = 232)

P Value

Demographics
 Age, y, median (IQR)
 Sex, male

66 (57.4–74.60)

59 (51.4–66.60)

64 (53–71)

107 (60.80)

29 (51.79)

41 (23.30)

23 (41.07)

64 (27.59)

166 (94.32)

51 (91.07)

217 (93.53)

.011

136 (58.62)

Current admission
 Intensive care unit admission
 Length of hospitalization, d, median (IQR)a

13 (3–23)

25 (13.1–36.9)

14 (8–31.5)

.009
<.001

Medical history
 Baseline comorbidities
  Heart/cardiovascular diseaseb

78 (44.32)

19 (33.93)

97 (41.81)

  Diabetes mellitus

60 (34.09)

21 (37.50)

81 (34.91)

  Chronic obstructive pulmonary disease

19 (10.80)

4 (7.14)

23 (9.91)

  Chronic kidney disease

34 (19.32)

11 (19.64)

45 (19.40)

  Liver disease

12 (6.82)

6 (10.71)

18 (7.76)

  Solid malignancy

52 (29.55)

7 (12.50)

59 (25.43)

  Hematological malignancy

57 (32.39)

30 (53.57)

87 (37.50)

4 (3–5.5)

4 (3–5)

4 (3–6)

  Charlson Comorbidity Index, median (IQR)
  Solid organ transplant

8 (3.45)

.098

  Bone marrow transplant

17 (9.66)

14 (25)

31 (13.36)

.003

  Immunosuppressive therapy

70 (39.77)

23 (41.07)

93 (40.09)

  Cardiac device and cardiac valve

26 (14.77)

5 (8.93)

31 (13.36)

  
Hemodialysis

26 (14.77)

11 (19.64)

37 (15.95)

121 (68.75)

50 (89.29)

171 (73.71)

 Nursing home/long-term facility

12 (6.82)

4 (7.14)

16 (6.90)

 Microbiological failurec

27 (15.34)

12 (21.43)

39 (16.81)

7 (3.98)

8 (14.29)

15 (6.47)

 Previous hospitalization within 1 y

 Recurrent BSId

4 (2.27)

4 (7.14)

.004

.002

.005

At the time of blood culture collection
 Recent surgical procedure

11 (6.25)

 Steroid use

21 (11.93)

14 (25)

5 (8.93)

35 (15.09)

16 (6.90)
.017

 Neutropenia, defined as <500 cells/µL

42 (23.86)

27 (48.21)

69 (29.74)

.001

 Central line placement

83 (47.16)

44 (78.57)

127 (54.74)

 Urinary catheter

35 (19.89)

18 (32.14)

53 (22.84)

.057

 Mechanical ventilation

16 (9.09)

12 (21.43)

28 (12.07)

.014

 Pitt bacteremia score ≥2

73 (41.48)

23 (41.07)

96 (41.38)
56 (24.14)

Index BSI episode
 Polymicrobial BSIe

43 (24.43)

13 (23.21)

 
Enterococcus faecium

36 (20.45)

50 (89.29)

86 (37.07)

<.001

 
Enterococcus faecalis

140 (79.55)

6 (10.71)

146 (62.93)

<.001

 Infectious diseases consult

146 (82.95)

50 (89.29)

196 (84.48)

 Endocarditis

15 (8.52)

4 (7.14)

19 (8.19)

 Subjects with echocardiogram

87 (49.43)

28 (50.00)

115 (49.57)

  Both (transthoracic and transesophageal)

1 (1.15)

5 (17.86)

10 (7–15)

12 (6–17.2)

10 (6.75–15)

  Central line infection

39 (22.16)

17 (30.36)

56 (24.14)

  
Genitourinary

25 (14.20)

3 (5.36)

28 (12.07)

  
Abdominal/gastrointestinal

46 (26.14)

11 (19.64)

57 (24.57)

  Unknown/primary source

63 (35.80)

21 (37.50)

84 (36.21)

3 (1.70)

4 (7.14)

7 (3.02)

 Monotherapy

110 (62.50)

35 (62.50)

145 (62.50)

  
β-lactamsh

47 (26.70)

6 (10.71)

53 (22.84)

.007

  
Daptomycin

30 (17.05)

23 (41.07)

53 (22.84)

<.001

   Daptomycin dose, mg/kg, median (IQR)

8 (6–8)

8 (8–10)

8 (6–10)

   
Daptomycin ≥10 mg/kg

6 (20)

9 (39.13)

15 (28.30)

 Duration of anti-enterococcal therapy, d (days)f

6 (5.22)

.015

Infection source

  
Wound/osteoarticular

.099

Definitive antimicrobial therapyg

.045
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 Reason of admission—medical

Table 1. Continued
Variables
  Vancomycin

VSE
(n = 176)

VRE
(n = 56)

Total Population
(N = 232)

30 (17.05)

2 (3.57)

32 (13.79)

  
Linezolid

2 (1.14)

4 (7.14)

6 (2.59)

  Tigecycline

1 (0.57)

0

1 (0.43)

 Combination therapy

55 (31.25)

  
Dual β-lactamsh

15 (8.52)

14 (25)
2 (3.57)

P Value
.031

69 (29.74)
17 (7.33)

9 (5.11)

0

9 (3.88)

.084

  Vancomycin plus β-lactamsh

9 (5.11)

0

9 (3.88)

.05

  
Daptomycin plus β-lactamsh

8 (4.55)

4 (7.14)

4 (2.27)

4 (7.14)

8 (3.45)

10 (5.68)

4 (7.14)

14 (6.03)

  Daptomycin plus linezolid
  
Otheri
  Daptomycin dose, mg/kg, median (IQR)
Empirical therapyj

8 (8–10)

8 (8–8)

12 (5.17)

8 (8–10)

138 (78.41)

47 (83.93)

185 (79.74)

  Vancomycin

74 (42.05)

18 (32.14)

92 (39.66)

  
β-lactamsh

71 (40.34)

19 (33.93)

90 (38.79)

  
Daptomycin

27 (15.34)

24 (42.86)

51 (21.98)

  
Linezolid

23 (13.07)

11 (19.64)

34 (14.66)

3 (1.70)

4 (7.14)

7 (3.02)

22 (12.50)

20 (35.71)

42 (18.10)

  Tigecycline

.098

<.001

Clinical outcomes
  In-hospital mortality

<.001

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; IQR, interquartile range; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.
a

Total days of hospitalization, including days before and after treatment of enterococcal bacteremia.

b

Categories of heart/cardiovascular diseases are not mutually exclusive. Conditions include ischemic heart disease, cerebrovascular disease, chronic heart failure, and peripheral vascular
disease.
c

Microbiological failure was defined as lack of clearance of BSI after ≥4 days of the index blood culture, while receiving at least 48 hours of active antibiotic therapy.

d

Recurrent BSI was defined as the presence of a new positive enterococcal blood culture in a patient who had previous negative blood culture.

e

Polymicrobial BSI was defined as the presence of ≥1 bacterial species other than enterococci in the same blood culture.

f

Including empiric and definitive therapy.

g

Definitive enterococcal therapy was defined as a drug with in vitro activity against the enterococcal isolate recovered from the bloodstream of the individual (after release of antibiotic
susceptibility results).
h

β-lactams include ampicillin, ampicillin-sulbactam, amoxicillin-clavulanic acid, ceftriaxone, or piperacillin-tazobactam.

i

Others include linezolid plus β-lactams (n = 6), daptomycin plus vancomycin (n = 2), tigecycline plus β-lactams (n = 2), gentamicin plus vancomycin (n = 1), daptomycin plus quinupristindalfopristin (n = 1), and daptomycin plus tigecycline (n = 2).
j

Defined as antibiotics given before antimicrobial susceptibility was available.

hospital site variable as a random effect (frailty) term in the
fixed-effects model. A similar analysis was performed for patients having a bloodstream infection secondary to E faecium.
Statistical significance was set at 2-tailed 5% level (P < .05).
Variables with >10% of missing data and/or a value ≤5 per category were excluded from the analysis. All analyses were performed using Stata 16.0 (StataCorp, College Station, Texas) and
R version 3.6.0. We also performed an unadjusted desirability
of outcome ranking (DOOR) [14, 15] analysis of the cumulative clinical events at 4, 7, 10, 12, and 15 days after the index
culture. Analyses consisted of estimating the probability that
a randomly selected patient with VRE vs VSE BSI had a more
desirable DOOR, with a probability of 50% implying no difference between DOOR distributions of the groups (eg, VRE vs
VSE). A probability of >50%—with a 95% bootstrap CI that excludes 50%—implies superiority of one group over the other.
CIs were calculated using 5000 bootstrap resamples. Major clinical events included MF and/or recurrence of BSI. The best outcome was defined as being alive without MF and/or recurrence
4 • OFID • Contreras et al

and the worst outcome was death. Thus, 3 levels were included:
(1) alive, (2) MF and/or recurrence, and (3) death. We also
performed a sensitivity analysis using an inverse probability
weighing Cox analysis to evaluate the association of VRE with
hospital mortality using the inverse of the propensity score as
weights (Supplementary Table 1).
Genome Sequencing and Analyses

Extraction of genomic DNA, library preparation, genome
sequencing (Illumina Platform), and initial analyses were performed as described previously [16–19] (see Supplementary
Materials for details). Paired-end sequencing data and genome assemblies are available under National Center for
Biotechnology Information BioProject PRJNA665052. Species
information was determined using BLASTn searches against
specific DNA sequences [20, 21] in a customized in silico polymerase chain reaction bioinformatics pipeline [22]. Multilocus
sequence typing was performed (https://github.com/tseemann/
mlst) by scanning contig files against the PubMLST database
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Gentamicin plus β-lactamsh

Patient Consent Statement

The protocol of this study was approved by the local institutional review board of participating institutions, which waived
the requirement for written or verbal consent from the patients
based on the observational nature of the study.
RESULTS

Between September 2016 and March 2018, 291 patients were
identified and 232 patients were included in the VENOUS I
study (Supplementary Figure 1). Among 232 patients, the median age was 64 years (IQR, 53–71 years), and 59% were male.
A detailed characterization of the overall cohort and a comparison between patients with VRE vs VSE BSIs are presented in
Table 1. Fifty-six (24%) individuals were infected with VRE,
whereas 176 (76%) patients had a VSE BSI. Subjects with VRE
BSI were younger (59 vs 66 years, P = .011) and more frequently
admitted to the intensive care unit than those with VSE infections (41% vs 23%, P = .009). VRE BSI was found more often in
subjects with hematological malignancy (53% vs 32%, P = .004)
or bone marrow transplant (25% vs 10%, P = .003). In addition,

Table 2.

patients with VRE BSI infection were more likely to be neutropenic at the time of diagnosis, have a central line, and on mechanical ventilation, as compared to those with VSE BSI (48%
vs 26%, 78% vs 47%, and 21% vs 9%, respectively). Of note, the
length of hospital stay was longer in individuals with VRE BSI
compared to VSE (25 vs 13 days, P < .001). The frequency of
polymicrobial BSI (isolation of bacterial species other than enterococci in the same blood culture) and the Pitt BSI score did
not differ between VRE and VSE BSIs (Table 1). As expected,
E faecium accounted for most VRE isolates (89%), whereas E
faecalis predominated among the cases of VSE (79%) (Table 1).
Daptomycin was the most common antibiotic used as monotherapy in subjects with VRE infections (median dose of 8 mg/
kg/day [IQR, 8–10 mg/kg]). Of note, 2 (3%) patients with VRE
infection were treated with vancomycin. One patient had a VSE
isolate but was later confirmed to be vancomycin-resistant E
faecium by whole genome sequencing. The second isolate was
deemed a contaminant by the infectious disease team since the
blood culture was obtained directly from a line (patient was
only treated with vancomycin for 48 hours after culture collection). Forty-two (18%) patients died during the study period
and 39 (17%) had MF. Of note, 15 (6%) patients had a recurrent
episode of enterococcal BSI. Recurrence was more frequent in
VRE compared to VSE BSIs (14% vs 4%; P = .005). The median follow-up duration was 10 days (IQR, 2–71 days), and the
median survival time was estimated to be 45 days (IQR, 38–51
days) after the first positive blood culture. The univariable analysis showed that mechanical ventilation (HR, 3.15 [95% CI,
1.60–6.10]), a Pitt BSI score ≥2 (HR, 2.72 [1.52–5.14]), MF (HR,
2.34 [95% CI, 1.22–4.47]), intensive care unit stay (HR, 2.22
[95% CI, 1.20–4.09]), VRE BSI (HR, 2.21 [95% CI, 1.20–4.10]),
central line placement (HR, 2.25 [95% CI, 1.09–4.61]), urinary
catheter (HR, 2.17 [95% CI, 1.17–4.02]), and absolute neutrophil count (ANC) <500 cells/μL (HR, 2.14 [95% CI, 1.50–5.14])
were associated with an increased rate of in-hospital mortality
(Table 2; see Supplementary Table 3 for additional variables).

Estimated Hazard Ratios of In-Hospital Mortality When Fitting a Univariable and Multivariate Cox Regression Model
Adjusted Conventionala,b

Unadjusted
Variable

HR

(95% CI)

P Value

HR

(95% CI)

P Value

Intensive care unit admission

2.22

(1.20–4.09)

.012

…

Pitt bacteremia score ≥2

2.72

(1.52–5.14)

.001

1.83

Neutropenia, defined as <500 cells/µL

2.78

(1.50–5.14)

(1.47–2.28)

<.001

.001

3.13

(2.89–3.39)

Central line placement

2.25

<.001

(1.09–4.61)

.028

…

Urinary catheter
Mechanical ventilation

2.17

(1.17–4.02)

.014

1.85

3.15

(1.60–6.10)

.001

…

VRE BSI

2.21

(1.20–4.10)

.011

2.13

(1.54–2.93)

<.001

Microbiological failure

2.34

(1.22–4.47)

.01

2.4

(1.34–4.31)

.003

…

…
(1.17–2.93)

.009

…

Abbreviations: BSI, bloodstream infection; CI, confidence interval; HR, hazard ratio; VRE, vancomycin-resistant enterococci.
a

Inclusion of variables in the adjusted model were determined through purposeful variable selection.

b

A hospital-specific random effect intercept was included in the model and was stratified by hospital unit of admission.
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to determine sequence type. Resistance genes were identified
from genome assemblies using previously defined approaches
for E faecium and adjusting the genomic characterization for E
faecalis (Supplementary Table 2 and Supplementary Materials)
[23]. Separate midpoint-rooted maximum-likelihood phylogenetic trees based on core genome alignment were created for E
faecalis and E faecium using RAxML [18] version 8.2.12 with
100 bootstrap iterations. Clade A and clade B reference genomes (AUS0004 and Com15, respectively) were included in
the E faecium tree to aid in determination of cladal division.
Trees were visualized using iTOL [19]. Determination of singlenucleotide polymorphisms (SNPs) and SNP threshold for E
faecium clade A isolates are described in the Supplementary
Materials.

A

B

Overall in-hospital mortality
VSE

compared to VSE, patients with a VRE infection were more likely
to have a worse outcome at all tested time-points, including at
day 15 (41% [95% CI, 34%–49%]) (Supplementary Table 7). We
also performed a sensitivity analysis to examine the robustness
of our results. Using inverse probability weighing with inverse
propensity scores as the weights to account for covariates that
predict the probability of having a VRE bloodstream infection, we confirmed that MF was the most consistent predictor
of in-hospital mortality in our cohort and that the impact of
VRE on mortality was not uniform throughout the observation
period. However, the sensitivity analyses suggested that the impact of VRE on in-hospital mortality was statistically significant at day 7 of bacteremia and the effect continued to day 10
(Supplementary Table 8).
The most common sequence types among the 146 E faecalis
isolates were ST6, ST179, and ST40 (Figure 2). Most of the
vanA-containing E faecalis (6/146) isolates were ST6 and concentrated in a single institution, and 5 of 6 appeared to be
highly related (Figure 2). Of note, all but one ST6 E faecalis
harbored aac(6’)-Ie-aph(2”)-Ia conferring high-level resistance
to gentamicin, and most were multidrug-resistant (MDR). No
genetic evidence of resistance to ampicillin (genes coding for
β-lactamase), linezolid (G2576 mutation on 23S ribosomal
RNA), or daptomycin (mutations in liaFSR) was identified in E
faecalis. The E faecium subset included 86 isolates representing
28 sequence types (Figure 3). Phylogenetic analysis showed the
previously described split between clade A (hospital-adapted)
and clade B (community-associated), with a variety of clade
B isolates causing BSIs [24]. More than half of E faecium isolates (50 of 86 [58.1%]) harbored the vanA gene cluster and
the majority of clade A isolates contained the “resistant” allele
of pbp5, resulting in increased minimum inhibitory concentrations (MICs) of ampicillin. Interestingly, we identified 18
vancomycin-resistant E faecium strains that harbored the W73C
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Figure 1. Kaplan-Meier estimates. Survival curves of patients with enterococcal bloodstream infection. A, Overall in-hospital mortality; dotted line shows that the effect
in mortality was not uniform throughout the observation period. B, Survival curve at day 2 of bacteremia. Curves are compared using the log-rank test and a value <.05 was
considered significant. Shaded areas represent 95% confidence intervals. Abbreviations: VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.
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The difference in mortality between VRE vs VSE became apparent at day 2 of the BSI (Figure 1A and 1B). Of note, the survival curves of VRE vs VSE indicated that the effect in mortality
was not uniform throughout the observation period (Figure 1,
dashed line). While this effect did not violate the statistical test
of the proportional hazards assumption, the Schoenfeld residuals were not linear (Supplementary Figure 2), so we chose to
model it as a time-dependent variable to account for the nonuniform proportional hazard over time. In contrast, this situation was not observed with Pitt BSI score, neutrophil count,
urinary catheter, or MF (Supplementary Figure 2A–E). The adjusted Cox analysis showed that an ANC <500 cells/µL, MF,
VRE BSI, Pitt BSI score ≥2, and use of urinary catheter were
associated with in-hospital mortality (Table 2). The interaction
between VRE and MF on in-hospital mortality was not significant and was not included in the final model (Supplementary
Table 4).
Since our analyses suggested that the influence of VRE BSI
on mortality changed during the course of the bloodstream episode, we evaluated the effect of VRE as a function of time at
days 4, 7, 10, 12, and 15 after the first positive blood culture to
test this hypothesis. The estimated HRs for these periods were
1.91, 1.68, 1.92, 2.48, and 7.02, respectively (Supplementary
Table 5). Thus, these findings indicated that the highest impact
on mortality of a VRE BSI was at day 15 (3.5-fold increase).
We restricted the analysis by species, and under that scenario
E faecium had a significantly higher impact on mortality compared to E faecalis (Supplementary Figure 3). Subsequently, we
restricted the analysis to only E faecium BSIs because the small
amount of vancomycin resistance in E faecalis (6 of 146; Table
1). Using this approach and the methods described above, MF
was the strongest predictor of in-hospital mortality in the multivariate analysis for E faecium (HR, 5.03 [95% CI, 3.25–7.77])
(Supplementary Table 6). DOOR analyses confirmed that,
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Figure 2. Phylogenetic and resistome analyses of Enterococcus faecalis from the Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I). Enterococcus
faecalis core gene-aligned, midpoint-rooted maximum likelihood phylogenetic tree with associated antibiotic resistance mechanisms (n = 146). The presence of a resistance
mechanism is denoted by a colored circle (genetic variant) or square (acquired resistance gene), with colors representing the class or type of antibiotic resistance conferred.
Gene abbreviations and descriptions can be found in Supplementary Table 2. Abbreviations: DH, Detroit hospital; HC, Houston cancer center; HH, Houston hospitals 1–9; ST,
sequence type.
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Figure 3. Phylogenetic and resistome analyses of Enterococcus faecium from the Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I). Enterococcus
faecium core gene-aligned, midpoint-rooted, maximum likelihood phylogenetic tree with associated antibiotic resistance mechanisms (n = 86) and cladal reference isolates.
The presence of a resistance mechanism is denoted by a colored circle (genetic variant) or square (acquired resistance gene), with colors representing the class or type of
antibiotic resistance conferred. Gene abbreviations and descriptions can be found in Supplementary Table 2. Abbreviations: DH, Detroit hospital; HC, Houston cancer center;
HH, Houston hospitals 1–9; ST, sequence type; ST-SV, single allelic variant of the respective sequence type.
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DISCUSSION

In this prospective, multicenter, observational cohort study that
spanned 2 years in multiple US hospitals, we show that the most
consistent factor impacting mortality in patients with enterococcal BSI is failure to eradicate the organism from the bloodstream. Indeed, MF remained the only factor affecting mortality
when analyzing patients infected with vancomycin-resistant vs
vancomycin-susceptible E faecium, the most recalcitrant and
difficult-to-treat species. Our findings are unique when compared to previous studies, which associated only vancomycin
resistance with increased risk of mortality regardless of species
[3, 10, 11, 27, 28]. This discrepancy is likely due to the fact that
previous studies are retrospective and lack microbiological assessments, since follow-up blood cultures were not considered
or available. Moreover, the definition of mortality applied by
several of these studies encompasses a broader period of observation (ie, 30-day mortality) rather than considering a clinically
relevant time window throughout the duration of the BSI.
To dissect the temporal impact of vancomycin resistance
on mortality, we used a time-covariate analysis in our cohort
and showed that the influence of vancomycin resistance on
mortality varied over the course of the disease. Furthermore, a
DOOR ranking outcome that included MF and/or recurrence
permitted comparison of the longitudinal effects of vancomycin
resistance on the overall clinical outcome. These novel findings
suggest that interventions targeted to early eradication of the
organisms in the bloodstream should be a priority in patients
with VRE BSI and that such benchmark should be included as
a major outcome when designing interventional trials. Since
there is an important degree of uncertainty on what is the best
therapy for MDR enterococci (particularly ampicillin- and
vancomycin-resistant E faecium), efforts to optimize therapies
for these organisms are urgently needed.
Our comprehensive genomic analyses yielded several conclusions. First, the proportion of E faecium carrying vanA was
lower than previously described (58%), and there was a marked
heterogeneity of genetic lineages of E faecium causing invasive
disease (rather than outbreaks). Nonetheless, some clustering
of isolates was found [5, 29, 30]. Second, we found genetically related E faecium isolates harboring mutations associated
with daptomycin resistance. Since daptomycin has become the

front-line antibiotic against VRE infection, the possible dissemination of these linages is a cause of major concern, particularly with the current uncertainties in MIC determination
[31]. Third, resistance to linezolid, the only US Food and Drug
Administration–approved antibiotic for VRE, was uncommon
both in E faecalis and E faecium in this cohort. Notably, the
genotypic prediction of daptomycin and linezolid resistance
remains to be confirmed by phenotypic tests since it was not
performed as a routine test. Finally, MDR E faecalis ST6 is the
predominant genetic lineage causing invasive disease in the
participating centers, most of them carrying resistance determinants to aminoglycosides and compromising the use of gentamicin for deep-seated infections due to E faecalis.
Several limitations need to be discussed. First, the participant hospitals are located in the US (2 cities), and our findings
may not be generalizable. Nonetheless, VRE are serious public
health threats in the US and the hospitals had a broad representation of patients who are at risk of acquiring VRE infections,
namely, critically ill, cancer, and immunocompromised patients [8]. Indeed, VRE tend to affect the same types of patients
regardless of geographical location, and we believe our cohort
is representative of the typical patients who develop enterococcal BSI. Second, since the study was exempt from informed
consent, the only data available were those in the electronic
medical record, and it is plausible that some data might have
been missed. For example, subsequent blood cultures beyond
7 days after index culture were at the discretion of the treating
physician, which may affect the determination of recurrence.
Thus, we could not include this variable in the final mortality
analyses due to this inconsistency in the cohort. Third, due to
the heterogeneity of treatment approaches, lack of information
related with infection source control, and low numbers, analyses to evaluate efficacy of antibiotics on MF and mortality
were not possible. The VENOUS cohort is being expanded and
we expect that, as the sample size increases, we will be able to
make more meaningful therapeutic comparisons. Fourth, our
study population was heterogeneous, and the observed impact
of VRE on mortality might be due to the presence of special
immunocompromised populations. Therefore, the weight of
VRE on mortality might also differ among patient populations.
Finally, the levels of mortality and DOOR analyses were arbitrarily chosen, but we believe they reflect “real-life” events of
clinical relevance.
In conclusion, in this unique prospective study of patients
with VRE and non-VRE BSI, MF was the most consistent factor
affecting poor outcomes. We found a temporal association of
VRE in outcomes, suggesting that early effective interventions
are critical to improve the outcomes of these vulnerable patients.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
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and T120A substitutions in LiaR and LiaS, respectively, that had
been previously associated with daptomycin resistance [25, 26].
These isolates belonged to ST584, ST1471, ST80, ST736, ST664,
ST412, and ST17 (Figure 3). Two major institution-specific
clade A E faecium clusters (≥5 isolates differing by <20 SNPs)
were identified based on SNP distances (Supplementary Figure
4) at a Houston cancer center (n = 5) and Detroit hospital
(n = 7), indicating potential sharing of clonally related isolates
between patients at these locations.

the authors, so questions or comments should be addressed to the corresponding author.
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